Abstract: Objective The aim of this study was to investigate the efficacy and safety of tenofovir disoproxil fumarate (TDF) and telbivudine (LdT)on blocking mother-to-child transmission of hepatitis B virus infection.Methods A total of 77 pregnant women with chrnonic hepatitis B virus infection were encruited in Tongliao Infectious Disease Hospital between May 2016 and May 2019, and 43 women took TDF and 34 women took LdT from 24th to 28th weeks of gestation to cessation of pregnance. All newborns received hepatitis B immunoglobulin within 6 hours of birth and yeast-derived recombinant hepatitis B vaccine at 0, 1, and 6 months after birth. Mothers and infants were followed for 7 months after infants’ birth.Results Serum HBV DNA load in TDF-treated women decreased from(7.4±1.2)lg copies/mL to (3.6±1.1)lg copies/mL(P＜0.05), and that in LdT-treated women decreased from (7.3±1.1)lg copies/mL to (4.1±1.2)lg copies/mL(P＜0.05) before and after treatment, and there was no significant difference between the two groups; there were no significant differences respect ot serum ALT levels before and after treatment in the two groups; seven months after birth, serum HBsAg were negative and serum HBsAb were positive in all infants in the two groups and there were no significant differences respect to body mass, lengths and circumferences of head of infants in the two groups (P>0.05); we didn’t observe any side effects in the two groups during the treatment.Conclusion The administration fo TDF LdT at the base of basic hepatitis B immunoglobulin and hepatitis B vaccine inoculation might effectively block mother-to-child hepatitis B virus transmission.

Key words: Hepatitis B virus carriers, Pregnancy, Mother-to-child transmission, Tenofovir disoproxil fumarate, Telbivudine, Prevention